anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thongprayoon et al. found in a study of 12,599 non-dialysis adult hospitalized patients that serum calcium (SC) disturbances affected more than half of the patients and were associated with increased in-hospital mortality. Similar impacts of SC disturbances on in-hospital mortality have been observed in patients with acute myocardial infarction and the general hospitalized population. Atrial fibrillation (AF), the most common arrhythmia in the intensive care unit (ICU), affects around 6% of critically ill patients. However, the significance of the relationship between SC levels and in-hospital mortality in these patients remains unclear. This study aimed to explore the correlation between SC levels and in-hospital mortality in ICU patients diagnosed with AF. Data from the MIMIC-IV database included 11,621 AF patients (average age 75.59 ± 11.74 years; 42.56% male), with an in-hospital mortality rate of 8.90%. A nonlinear relationship between SC levels and in-hospital mortality was observed. Effect sizes on either side of the inflection point were 0.79 (HR: 0.79, 95% CI 0.67-0.94, P = 0.006) and 1.12 (HR: 1.12, 95% CI 1.01-1.25, P = 0.029). Sensitivity analyses confirmed these results. SC levels around 8.56 mg/dL were associated with the lowest risk of in-hospital mortality, with risks increasing as SC levels deviated from this point. SC levels below this inflection point were linked to more pronounced clinical impacts. This finding has significant clinical implications for clinicians. Therefore, in the treatment of ICU patients with AF, clinicians should closely monitor SC levels, with a focus on maintaining them around 8.56 mg/dL.
BACKGROUND: The development of pulmonary fibrosis involves a cascade of events, in which inflammation mediated by immune cells plays a pivotal role. Chemotherapeutic drugs have been shown to have dual effects on fibrosis, with bleomycin exacerbating pulmonary fibrosis and bortezomib alleviating tissue fibrotic processes. Understanding the intricate interplay between chemotherapeutic drugs, immune responses, and pulmonary fibrosis is likely to serve as the foundation for crafting tailored therapeutic strategies.
METHODS: A model of bleomycin-induced pulmonary fibrosis was established, followed by treatment with bortezomib. Tissue samples were collected for analysis of immune cell subsets and functional assessment by flow cytometry and in vitro cell experiments. Additionally, multi-omics analysis was conducted to further elucidate the expression of chemokines and chemokine receptors, as well as the characteristics of cell populations.
RESULTS: Here, we observed that the expression of CXCL16 and CXCR6 was elevated in the lung tissue of a pulmonary fibrosis model. In the context of pulmonary fibrosis or TGF-β1 stimulation in vitro, macrophages exhibited an M2-polarized phenotype and secreted more CXCL16 than those of the control group. Moreover, flow cytometry revealed increased expression levels of CD69 and CXCR6 in pulmonary CD4 T cells during fibrosis progression. The administration of bortezomib alleviated bleomycin-induced pulmonary fibrosis, accompanied by reduced ratio of M2-polarized macrophages and decreased accumulation of CD4 T cells expressing CXCR6.
CONCLUSIONS: Our findings provide insights into the key immune players involved in bleomycin-induced pulmonary fibrosis and offer preclinical evidence supporting the repurposing strategy and combination approaches to reduce lung fibrosis.
A kind of people, with blood sugar lowering Weight-reducing and lipid-lowering compound preparation, belongs to biomedicine technical field. there is the essential active of following relative weight share: Semen Phaseoli Vulgaris alpha-amylase inhibitor 0.002��0.5 part, Semen Phaseoli Vulgaris phytohemagglutinin 0.001��0.03 part, Ipomoea hungaiensis Lingelsh. Et Borza. 0.1��0.4 part or by same share Ipomoea hungaiensis Lingelsh. Et Borza. gained water extract, and one or more having in the selective active component of following relative weight share: tremella polysaccharide 0.05��0.2 part, Fructus Crataegi 0.1��0.3 part or by same share Fructus Crataegi gained water extract, Semen Cassiae 0.1��0.2 part or by same share Semen Cassiae gained water extract, Radix Salviae Miltiorrhizae 0.1��0.2 part or by same share Radix Salviae Miltiorrhizae gained water extract, the Radix Astragali 0.1��0.2 part or by same share Radix Astragali gained water extract, dietary fiber 0.1��0.3 part or by same share dietary fiber gained water extract. for pure natural material combination preparation, can have blood sugar lowering simultaneously, fat-reducing, blood fat reducing and hypotensive effect.
A pharmacy workstation includes a staging area where a prescription is initially processed by entering prescription data and customer data into a computer operable with a keyboard and recessed monitor. A prescription filling process area downstream the staging area yet proximate the keyboard includes a telephone and printer for communicating information with a doctor and insurance provider, as desired. A slot within the counter permits printed material, including prescription and customer information, and printed labels to be conveniently delivered to the process area. Gravity fed bins store empty vials and caps. A drug-filled vial, the written prescription, and the printed material are placed in a basket and conveyed downstream to a checking process area of the workstation. Once checked, the capped vial is placed in a bag, the bag sealed, and conveyed to a finished prescription holding area.
Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
This cohort consists of patients aged 18 years or older who are undergoing elective cosmetic surgery. All participants in this group have undergone an AI-powered Body Dysmorphic Disorder (BDD) screening, which includes the completion of the Body Dysmorphic Disorder Questionnaire (BDDQ) and additional psychological evaluations. The AI system provides a risk assessment for BDD, guiding the surgical decision-making process and identifying patients who may require psychological intervention before proceeding with surgery.
PCT No. PCT/DK82/00082 Sec. 371 Date Apr. 11, 1983 Sec. 102(e) Date Apr. 11, 1983 PCT Filed Sep. 14, 1982 PCT Pub. No. WO83/01074 PCT Pub. Date Mar. 31, 1983.Human insulin or B-30 esters thereof are prepared by reacting an insulin derivative of the formula < IMAGE > (I) wherein R is hydroxyl or an amino acid radical being different from threonine, and -A- and -B- represent the A- and B-chains with the same amino acid sequence as in human insulin, with a carboxyl protected and optionally hydroxyl protected L-threonine derivative in a concentration of from 2 to about 6 moles per liter in the presence of trypsin or a trypsin-like enzyme in a reaction medium containing water and optionally also an organic cosolvent at a pH value of from 5 to 9 and at a temperature below 50 DEG C., followed, if desired, by removal of any protecting groups present. Human insulin is prepared in an easy and simple way in high yield and in high purity.
An apparatus and method for generating a prescription form is disclosed. The method includes displaying a first menu containing a plurality of therapy menu items. The method also includes displaying a second menu containing at least one qualifier menu item. The method further includes displaying a third menu containing at least one drug menu item. The method includes, upon selection of a therapy menu item, a qualifier menu item, and a drug menu item, selecting a protocol including one or more patient specific pump parameters corresponding to the therapy menu item, the qualifier menu item, and the drug menu item. The method also includes displaying a prescription form including at least one of the one or more patient specific pump parameters.
This study tests a group model of Family Nurture Intervention (FNI), a novel family-based intervention that facilitates mother-child emotional connectedness and co-regulation. Many current interventions aim at helping the child to self-regulate with or without the mother's help. However, according to the investigators' Calming Cycle Theory, the ability of the mother-child dyad to promote optimal development is dependent on the dyad's ability to co-regulate. The interactive co-regulation between the mother and the child shapes the behavior of both. This study aims to investigate the short and long term effects of FNI in a multiple family group setting for preschool aged children to prevent and/or treat developmental/behavioral problems.

Previously, FNI implemented in the Neonatal Intensive Care Unit (NICU) for premature infants and their mothers at Columbia University Medical Center demonstrated that FNI positively alters neurodevelopment of premature infants. Infants who received FNI in the NICU demonstrated increased brain activity in the prefrontal cortex at term age, improved cognitive and language development at 18 months as measured by the Bayley Scales of Infant Development, improved behavior on the Child Behavior Checklist (CBCL) and reduced risk for autism as indicated by the Modified Checklist for Autism in Toddlers (M-CHAT) at 18 months. The pilot study of FNI with preschool aged children and their mothers shows a 40% reduction in behavioral problems on the CBCL. Accordingly, the investigators hypothesize that the Family Nurture Intervention will alter physiological regulatory capacities and will result in improved indices of mother-child emotional connection and other outcomes in the preschool population similar to the results in the preterm population.
The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8.

Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions.
Subjects in A arm (Group 1 Menthol) will be required to smoke Ploom HTP Menthol HTS; MX3 (681) study product at least 5 times per day ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
BACKGROUND AND OBJECTIVE: Coronary plaque rupture is a precipitating event responsible for two thirds of myocardial infarctions. Currently, the risk of plaque rupture is computed based on demographic, clinical, and image-based adverse features. However, using these features the absolute event rate per single higher-risk lesion remains low. This work studies the power of a novel framework based on biomechanical markers accounting for material uncertainty to stratify vulnerable and non-vulnerable coronary plaques.
METHODS: Virtual histology intravascular ultrasounds from 55 patients, 29 affected by acute coronary syndrome and 26 affected by stable angina pectoris, were included in this study. Two-dimensional vessel cross-sections for finite element modeling (10 sections per plaque) incorporating plaque structure (medial tissue, loose matrix, lipid core and calcification) were reconstructed. A Montecarlo finite element analysis was performed on each section to account for material variability on three biomechanical markers: peak plaque structural stress at diastolic and systolic pressure, and peak plaque stress difference between systolic and diastolic pressures, together with the luminal pressure. Machine learning decision tree classifiers were trained on 75% of the dataset and tested on the remaining 25% with a combination of feature selection techniques. Performance against classification trees based on geometric markers (i.e., luminal, external elastic membrane and plaque areas) was also performed.
RESULTS: Our results indicate that the plaque structural stress outperforms the classification capacity of the combined geometric markers only (0.82 vs 0.51 area under curve) when accounting for uncertainty in material parameters. Furthermore, the results suggest that the combination of the peak plaque structural stress at diastolic and systolic pressures with the maximum plaque structural stress difference between systolic and diastolic pressures together with the systolic pressure and the diastolic to systolic pressure gradient is a robust classifier for coronary plaques when the intrinsic variability in material parameters is considered (area under curve equal to [0.91-0.93]).
CONCLUSION: In summary, our results emphasize that peak plaque structural stress in combination with the patient's luminal pressure is a potential classifier of plaque vulnerability as it independently considers stress in all directions and incorporates total geometric and compositional features of atherosclerotic plaques.
Motor weakness has been reported rarely in patients receiving combination antiretroviral therapy including stavudine. Most of these cases occurred in the setting of lactic acidosis. The evolution of motor weakness may mimic the clinical presentation of Guillain-Barre syndrome (including respiratory failure). If motor weakness develops, stavudine should be discontinued. Symptoms may continue or worsen following discontinuation of therapy.

Peripheral sensory neuropathy, manifested by numbness, tingling, or pain in the hands or feet, has been reported in patients receiving stavudine therapy. Peripheral neuropathy, which can be severe, is dose-related and occurs more frequently in patients with advanced HIV-1 disease, a history of peripheral neuropathy, or in patients receiving other drugs that have been associated with neuropathy [see Drug Interactions (7)].

Patients should be monitored for the development of peripheral neuropathy. Stavudine-related peripheral neuropathy may resolve if therapy is withdrawn promptly. If peripheral neuropathy develops permanent discontinuation of stavudine should be considered. In some cases, symptoms may worsen temporarily following discontinuation of therapy.
Age-related morbidity has become an increasingly significant issue worldwide. Sarcopenia, the decline in skeletal muscle mass and strength with age, has been reported to be a risk factor for cognitive impairment. Our previous study revealed that skeletal muscle atrophy shifts the onset of memory dysfunction earlier in young Alzheimer's disease mice and found that hemopexin is a myokine responsible for memory loss. This study aimed to elucidate the occurrence of memory impairment due to skeletal muscle atrophy in non-genetically engineered healthy young mice and the involvement of hemopexin. Closed-colony ddY mice at 12-13 weeks of age were used. Both hind limbs were immobilized by cast attachment for 14 d. Casting for 2 weeks induced a loss of skeletal muscle weight. The memory function of the mice was evaluated using a novel object recognition test. The cast-attached mice exhibited memory impairment. Hemopexin levels in the conditioned medium of the skeletal muscle, plasma, and hippocampus were increased in cast-attached mice. Continuous intracerebroventricular hemopexin infusion induced memory deficits in non-cast mice. To investigate whether hemopexin is the main causative factor of cognitive impairment, cast-attached mice were intracerebroventricularly infused with an anti-hemopexin antibody. Cast-induced memory impairment was reversed by the infusion of an anti-hemopexin antibody. These findings provide new evidence that skeletal muscle atrophy causes memory impairment in healthy young mice through the action of hemopexin in the brain.
Validation Group: dosage group of 12 subjects, 4 will receive 4.8 RT-PCR units and 8 will receive 0.48 RT-PCR units of Lot 42399 NV. No placebo control.
The present invention discloses a medicine for treating chronic layngopharyngitis and a preparation process thereof. The medicine has the raw materials of cicada slough, ophiopogon root and boat-fruited sterculia. The preparation process comprises the steps that the proportional mixture of the cicada slough, the ophiopogon root and the boat-fruited sterculia is decocted for twice with water, namely decocted for 2 hours with water accounting for 8 times of the weight of the mixture at the first time and decocted for 1 hour with water accounting for 6 times of the weight of the mixture at the second time; the decocted liquids are filtered and mixed; the mixed decocted liquid is concentrated to a liquid with the relative density of 1.1 to 1.2 (50 DEG C); the concentrated liquid is cooled, refrigerated for 24 hours and filtered and the total amount of the concentrated liquid is regulated to 1000 ml; then, the concentrated liquid is filled into bottles, sealed and sterilized to aqueous agents or tablets in bottles. The medicine has a refined formula, wherein the ophiopogon root in the medicine contains various steroid saponins, the boat-fruited sterculia contains astragalus glue, and the steroid saponins and the astragalus glue can be combined with the water extract of the cicada slough to exert a curative effect together. The medicine has the functions of heat clearing for throat soreness relief and yin nourishing for throat moistening, is used for treating swellings and pains in the throat, hoarse voice, etc. due to the chronic layngopharyngitis, and has the advantages of wide medicine source and low price, and a prepared Chinese medicine with outstanding curative effect and no toxic or side effect is suitable for patients to use at any time.
BACKGROUND: Chronic kidney disease (CKD) is a significant public health concern. Therefore, practical strategies for slowing CKD progression and improving patient outcomes are imperative. There is limited evidence to substantiate the efficacy of mobile app-based nursing systems for decelerating CKD progression.
OBJECTIVE: This study aimed to evaluate the long-term efficacy of the KidneyOnline intelligent care system in slowing the progression of nondialysis-dependent CKD.
METHODS: In this retrospective study, the KidneyOnline app was used for patients with CKD in China who were registered between January 2017 and April 2023. Patients were divided into 2 groups: an intervention group using the app's nurse-led, patient-oriented management system and a conventional care group that did not use the app. Patients' uploaded health data were processed via deep learning optical character recognition, and the artificial intelligence (AI) system provided personalized health care plans and interventions. Conversely, the conventional care group received suggestions from nephrologists during regular visits without AI. Monitoring extended for an average duration of 2.1 (SD 1.4) years. The study's objective is to assess the app's effectiveness in preserving kidney function. The primary outcome was the estimated glomerular filtration rate slope over the follow-up period, and secondary outcomes included changes in albumin-to-creatinine ratio (ACR) and mean arterial pressure.
RESULTS: A total of 12,297 eligible patients were enrolled for the analysis. Among them, 808 patients were successfully matched using 1:1 propensity score matching, resulting in 404 (50%) patients in the KidneyOnline care system group and another 404 (50%) patients in the conventional care group. The estimated glomerular filtration rate slope in the KidneyOnline care group was significantly lower than that in the conventional care group (odds ratio -1.3, 95% CI -2.4 to -0.1 mL/min/1.73 m2 per year vs odds ratio -2.8, 95% CI -3.8 to -1.9 mL/min/1.73 m2 per year; P=.009). Subgroup analysis revealed that the effect of the KidneyOnline care group was more significant in male patients, patients older than 45 years, and patients with worse baseline kidney function, higher blood pressure, and heavier proteinuria. After 3 and 6 months, the mean arterial pressure in the KidneyOnline care group decreased to 85.6 (SD 9.2) and 83.6 (SD 10.5) mm Hg, respectively, compared to 94.9 (SD 10.6) and 95.2 (SD 11.6) mm Hg in the conventional care group (P<.001). The ACR in the KidneyOnline care group showed a more significant reduction after 3 and 6 months (736 vs 980 mg/g and 572 vs 840 mg/g; P=.07 and P=.03); however, there was no significant difference in ACR between the two groups at the end of the follow-up period (618 vs 639 mg/g; P=.90).
CONCLUSIONS: The utilization of KidneyOnline, an AI-based, nurse-led, patient-centered care system, may be beneficial in slowing the progression of nondialysis-dependent CKD.
PURPOSE:To remove a blood serum cholesterol rise promoting factor, by subjecting wheat bran to enzymic treatment with glucoamylase, chemical treatment, e.g. heat treatment in an aqueous solution of an organic acid, etc., physical treatment by washing with high-speed rotating and stirring, etc. CONSTITUTION:Wheat bran which is part other than wheat flour obtained in grinding wheat into fine powder is subjected to enzymic treatment, chemical treatment, physical treatment or combined treatment thereof to remove a blood serum cholesterol rise promoting factor. The chemical treatment means treatment by using one or more of starch hydrolase, e.g. glucoamylase, alpha-amylase, etc., proteolytic enzyme, e.g. pancreatin, protease, etc., fat hydrolase, cellulolytic enzyme, etc. The chemical treatment means heat treatment with a surfactant, extraction treatment with an organic solvent, etc. The physical treatment means washing with high-speed rotating and stirring using a juicer mixer, homogenizer, etc.
One weekly treatment with acupuncture in five consecutive weeks. In trial week 1-5 Group E will receive treatment and Group L will act as control group.
A contract fee is obtained from the one or more licensed medical professionals who may lease all or part of a hearing center. The lease fee is applied exclusively to expenses associated with a hearing center and the hearing center utilizes an Audiologist or Hearing Instrument Specialist. The patient is screened by the one or more licensed medical professionals according to one or more first screening methods. When the first screening indicates a potential hearing problem with the patient, the patient is referred to the hearing center. The patient undergoes an audiometric exam by the Audiologist or Hearing Instrument Specialist for hearing loss at the hearing center. When the testing by the Audiologist or Hearing Instrument Specialist indicates a need for a hearing instrument, a hearing instrument is ordered from the hearing instrument supplier. The hearing aid is fitted to the patient by the Audiologist or Hearing Instrument Specialist onsite at the hearing center. The profit to participating medical professionals is determined by the number of referrals that practitioner generates and sends to the Hearing Center that also result in sales of hearing instruments.
Sham stimulation will be performed for five consecutive days for 2 weeks (using 90% of the resting motor threshold/total of 500 pulses). For the sham stimulation a sham coil will be used.
Supplementation of Placebo of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.